利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

94 条记录 (耗时 0.029 秒)

    MODIFIED VACCINIA ANKARA VIRUS VARIANT
    2.
    发明申请
    MODIFIED VACCINIA ANKARA VIRUS VARIANT 审中-公开
    改良的VACCINIA ANKARA VIRUS变种

    公开(公告)号：US20120328650A1

    公开(公告)日：2012-12-27

    申请号：US13588217

    申请日：2012-08-17

    申请人： PAUL CHAPLIN ,  PAUL HOWLEY ,  CHRISTINE MEISINGER-HENSCHEL

    发明人： PAUL CHAPLIN ,  PAUL HOWLEY ,  CHRISTINE MEISINGER-HENSCHEL

    IPC分类号： A61K39/275 ,  A61P31/12 ,  A61K39/295

    CPC分类号： C07K14/005 ,  A61K39/12 ,  A61K39/285 ,  A61K48/00 ,  A61K2039/5254 ,  A61K2039/5256 ,  A61K2039/53 ,  A61K2039/545 ,  C12N7/00 ,  C12N15/86 ,  C12N2710/24121 ,  C12N2710/24143 ,  C12N2740/16322

    摘要： The present invention provides an attenuated virus, which is derived from Modified Vaccinia Ankara virus, wherein the MVA-BN virus, or a derivative thereof, induces at least substantially the same level of immunity in vaccinia virus prime/vaccina virus boost regimes when compared to DNA prime/vaccinia virus boost regimes. It further describes recombinant viruses derived from this virus and the use of the virus, or its recombinants, as a medicament or vaccine. A method is provided for inducing an immune response in individuals who may be immune-compromised, receiving antiviral therapy, or have a pre-existing immunity to the vaccine virus.

    摘要翻译： 本发明提供了一种减毒病毒，其来源于改良的痘苗病毒安卡拉病毒，其中MVA-BN病毒或其衍生物在痘苗病毒原/疫苗病毒增强方案中诱导至少基本相同的免疫水平， DNA原核/痘苗病毒增强体系。 它还描述了源自该病毒的重组病毒和病毒或其重组体作为药物或疫苗的用途。 提供了一种方法，用于在可能被免疫损害的个体中诱导免疫应答，接受抗病毒治疗或具有疫苗病毒的预先存在的免疫。

    Modified Vaccinia Ankara virus variant
    5.
    发明授权
    Modified Vaccinia Ankara virus variant 有权
    改良牛痘安卡拉病毒变体

    公开(公告)号：US08268325B2

    公开(公告)日：2012-09-18

    申请号：US13053361

    申请日：2011-03-22

    申请人： Paul Chaplin ,  Paul Howley ,  Christine Meisinger-Henschel

    发明人： Paul Chaplin ,  Paul Howley ,  Christine Meisinger-Henschel

    IPC分类号： A61K39/12

    CPC分类号： C07K14/005 ,  A61K39/12 ,  A61K39/285 ,  A61K48/00 ,  A61K2039/5254 ,  A61K2039/5256 ,  A61K2039/53 ,  A61K2039/545 ,  C12N7/00 ,  C12N15/86 ,  C12N2710/24121 ,  C12N2710/24143 ,  C12N2740/16322

    摘要： The present invention provides an attenuated virus, which is derived from Modified Vaccinia Ankara virus, wherein the MVA-BN virus, or a derivative thereof, induces at least substantially the same level of immunity in vaccinia virus prime/vaccina virus boost regimes when compared to DNA prime/vaccinia virus boost regimes. It further describes recombinant viruses derived from this virus and the use of the virus, or its recombinants, as a medicament or vaccine. A method is provided for inducing an immune response in individuals who may be immune-compromised, receiving antiviral therapy, or have a pre-existing immunity to the vaccine virus.

    摘要翻译： 本发明提供了一种减毒病毒，其来源于改良的痘苗病毒安卡拉病毒，其中MVA-BN病毒或其衍生物在痘苗病毒原/疫苗病毒增强方案中诱导至少基本相同的免疫水平， DNA原核/痘苗病毒增强体系。 它还描述了源自该病毒的重组病毒和病毒或其重组体作为药物或疫苗的用途。 提供了一种方法，用于在可能被免疫损害的个体中诱导免疫应答，接受抗病毒治疗或具有疫苗病毒的预先存在的免疫。

    Modified Vaccinia Ankara virus variant and cultivation method
    6.
    发明授权
    Modified Vaccinia Ankara virus variant and cultivation method 有权
    改良牛痘安卡拉病毒变种及培养方法

    公开(公告)号：US08236560B2

    公开(公告)日：2012-08-07

    申请号：US13106176

    申请日：2011-05-12

    申请人： Paul Chaplin ,  Paul Howley ,  Christine Meisinger-Henschel ,  Ingmar Rathe ,  Eva Felder ,  Karl Heller

    发明人： Paul Chaplin ,  Paul Howley ,  Christine Meisinger-Henschel ,  Ingmar Rathe ,  Eva Felder ,  Karl Heller

    IPC分类号： A01N63/00

    CPC分类号： A61K39/285 ,  A61K39/12 ,  A61K48/00 ,  A61K2039/5254 ,  A61K2039/5256 ,  A61K2039/53 ,  A61K2039/545 ,  C07K14/005 ,  C12N7/00 ,  C12N15/86 ,  C12N2710/24134 ,  C12N2710/24143 ,  C12N2710/24151 ,  C12N2740/16322

    摘要： The present invention provides an attenuated virus, which is derived from Modified Vaccinia Ankara virus and characterized by the loss of its capability to reproductively replicate in human cell lines. It further describes recombinant viruses derived from this virus and the use of the virus, or its recombinants, as a medicament or vaccine. A method is provided for inducing an immune response in individuals who may be immune-compromised, receiving antiviral therapy, or have a pre-existing immunity to the vaccine virus. In addition, a method is provided for the administration of a therapeutically effective amount of the virus, or its recombinants, in a vaccinia virus prime/vaccinia virus boost inoculation regimen. The present invention relates to a method of virus amplification in primary cells which are cultivated in a serum free medium. Viruses produced by this method are advantageously free of any infectious agents comprised in animal sera.

    摘要翻译： 本发明提供一种减毒病毒，其衍生自改良的痘苗安卡拉病毒，其特征在于丧失其在人细胞系中繁殖复制的能力。 它还描述了源自该病毒的重组病毒和病毒或其重组体作为药物或疫苗的用途。 提供了一种方法，用于在可能被免疫损害的个体中诱导免疫应答，接受抗病毒治疗或具有疫苗病毒的预先存在的免疫。 此外，提供了一种用于在痘苗病毒原/痘苗病毒加强接种方案中施用治疗有效量的病毒或其重组体的方法。 本发明涉及在无血清培养基中培养的原代细胞中的病毒扩增方法。 通过该方法产生的病毒有利地不含动物血清中包含的任何传染性物质。

    Fusion protein of HIV regulatory/accessory proteins
    7.
    发明授权
    Fusion protein of HIV regulatory/accessory proteins 失效
    HIV调节/辅助蛋白融合蛋白

    公开(公告)号：US08143054B2

    公开(公告)日：2012-03-27

    申请号：US12490424

    申请日：2009-06-24

    申请人： Paul Howley ,  Sonja Leyrer ,  Eva Felder

    发明人： Paul Howley ,  Sonja Leyrer ,  Eva Felder

    IPC分类号： C12N15/00 ,  A61K39/21 ,  A61K39/275 ,  A61K39/12

    CPC分类号： C12N15/86 ,  A61K39/12 ,  A61K39/21 ,  A61K2039/5256 ,  A61K2039/53 ,  C07K14/005 ,  C07K2319/00 ,  C07K2319/40 ,  C12N2710/24143 ,  C12N2740/16322 ,  C12N2740/16334

    摘要： The invention relates to fusion proteins comprising the amino acid sequence of at least three HIV proteins selected from Vif, Vpr, Vpu, Rev, and Tat or derivatives of the amino acid sequence of one or more of said proteins, wherein the fusion protein is not processed to individual HIV proteins having the natural N and C termini. The invention further concerns nucleic acids encoding said proteins, vectors comprising said nucleic acids, and methods for producing said proteins. The fusion protein, nucleic acids and vectors are usable as vaccines for the at least partial prophylaxis against HIV infections.

    摘要翻译： 本发明涉及包含选自Vif，Vpr，Vpu，Rev和Tat的至少三种HIV蛋白质的氨基酸序列或一种或多种所述蛋白质的氨基酸序列的衍生物的融合蛋白，其中融合蛋白不是 加工成具有天然N和C末端的单独的HIV蛋白质。 本发明还涉及编码所述蛋白质的核酸，包含所述核酸的载体和用于产生所述蛋白质的方法。 融合蛋白，核酸和载体可用作用于至少部分预防HIV感染的疫苗。